Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Wuxi Biologics Inc.
Headquarters: Shanghai, China
Website: http://www.wuxibiologics.com...
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Zhi Sheng Chen, PhD
Number Of Employees: N/A
Enterprise Value: $9,269,150,492
PE Ratio: 30.07
Exchange/Ticker 1: HKEX:2269
Exchange/Ticker 2: N/A
Latest Market Cap: $14,152,591,968
BioCentury | Mar 26, 2025
Data Byte
China deals look beyond cancer
At least eight East-to-West licensing deals outside oncology so far this year
BioCentury | Mar 18, 2025
Data Byte
Wuxi stocks bounce back as Biosecure threat fades
Shares of Wuxi Apptec and Wuxi Biologics are closing in on pre-Biosecure levels
BioCentury | Feb 26, 2025
Management Tracks
Lindsay Androski named CEO of Arbutus
Plus: CMO Maria Koehler steps down at Repare, and updates from Isomab, Crescent, Ottimo and Senti Bio
BioCentury | Jan 7, 2025
Deals
Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC
BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more
BioCentury | Dec 31, 2024
Finance
Biotech raises make 2024 the year of the PIPE
BioCentury’s final Public Equity Report of the year tallies up fundraising activity
BioCentury | Dec 31, 2024
Deals
Drumbeat of China deals steady through year-end
Wuxi Apptec moves to preserve its core interests, GLP-1R deals showcase breadth of China biotech’s dealmaking
BioCentury | Dec 9, 2024
Politics, Policy & Law
Biosecure setback amid lawmakers’ push to reduce reliance on China
Defense bill places biotech under national security umbrella
BioCentury | Dec 5, 2024
Politics, Policy & Law
Biosecure compromise in the works, fate uncertain as deadline nears
Deal among lawmakers would give targeted companies chance to avoid sanctions
BioCentury | Nov 19, 2024
Politics, Policy & Law
As Congress considers Biosecure, report says WuXi companies low-risk
Rhodium Group report suggests Congress focus on economic rather than military threats from China biotech
BioCentury | Nov 14, 2024
Data Byte
Cross-border trends in uncertain times for China biotech
A new start-up model and licensing deals fueled by new modalities sustain the momentum of China biotech’s innovation engine
Items per page:
1 - 10 of 176